Over the last 18 months, MindMed has undergone an extraordinary transformation. It released compelling data for its LSD-based drug MM120, followed by FDA breakthrough designation for MM120 for the treatment of GAD, and strong financial backing. CEO Rob Barrow outlines the company's ambitious goals and the path to potentially transforming mental healthcare at RBC's Global Healthcare Conference.

<description>&lt;p&gt;Over the last 18 months, MindMed has undergone an extraordinary transformation. It released compelling data for its LSD-based drug MM120, followed by FDA breakthrough designation for MM120 for the treatment of GAD, and strong financial backing. CEO Rob Barrow outlines the company's ambitious goals and the path to potentially transforming mental healthcare at RBC's Global Healthcare Conference.&lt;/p&gt;</description>

MindMed: Rethinking brain health with psychedelic therapy

Eyepoint CFO George Elston provides insights on the evolving space of retinal disease treatment, focusing on capital allocation, medical innovation, industry engagement and financial prudence.

<description>&lt;p&gt;Eyepoint CFO George Elston provides insights on the evolving space of retinal disease treatment, focusing on capital allocation, medical innovation, industry engagement and financial prudence. &lt;/p&gt;</description>

Funding the future of retinal health with Eyepoint

Paris Panayiotopoulos, Senior Managing Director at Blackstone Life Sciences, shares how the firm’s broad life sciences strategy has been advancing innovation across the life sciences ecosystem in three key ways: late-stage product financing (Collaboration) and new company creation (Ownership), and non-dilutive financing (Credit and Royalties). He explains how Blackstone is bridging the innovation funding gap through high-conviction partnerships with larger BioPharma and MedTech companies, and targeted investment in late-stage trials.

<description>&lt;p&gt;Paris Panayiotopoulos, Senior Managing Director at Blackstone Life Sciences, shares how the firm’s broad life sciences strategy has been advancing innovation across the life sciences ecosystem in three key ways: late-stage product financing (Collaboration) and new company creation (Ownership), and non-dilutive financing (Credit and Royalties). He explains how Blackstone is bridging the innovation funding gap through high-conviction partnerships with larger BioPharma and MedTech companies, and targeted investment in late-stage trials.&lt;/p&gt;</description>

How Blackstone Life Sciences is bridging the innovation gap

Compass Pathways CEO Kabir Nath believes psilocybin-based therapy could be transformational for patients with treatment-resistant depression—and his company is already preparing to deliver it at scale. Speaking at RBC Capital Markets’ Global Healthcare Conference, Nath shares his vision for Compass and the future of psilocybin therapy for treatment-resistant depression.

<description>&lt;p&gt;Compass Pathways CEO Kabir Nath believes psilocybin-based therapy could be transformational for patients with treatment-resistant depression—and his company is already preparing to deliver it at scale. Speaking at RBC Capital Markets’ Global Healthcare Conference, Nath shares his vision for Compass and the future of psilocybin therapy for treatment-resistant depression.&lt;/p&gt;</description>

Compass trials mark a milestone moment for the psychedelics sector

Every year, flu vaccine manufacturers have to guess what strains to target next season, with varying success. <a href="https://www.cidara.com/" rel="noopener noreferrer" target="_blank">Cidara Therapeutics</a> believes it may have a better alternative. President and CEO Jeff Stein explains how Cidara's laser-like focus on developing CD388, a single-dose antiviral targeting all flu strains, has brought the 40-person company on the verge of a public health breakthrough.<a href="https://www.cidara.com/news/cidara-therapeutics-announces-positive-topline-results-from-its-phase-2b-navigate-trial-evaluating-cd388-a-non-vaccine-preventative-of-seasonal-influenza/" rel="noopener noreferrer" target="_blank">Cidara announces positive topline results from its phase 2b NAVIGATE trial evaluating CD388</a><a href="https://www.cidara.com/about/#leadership" rel="noopener noreferrer" target="_blank">President and CEO Jeff Stein Bio</a>

<description>&lt;p&gt;Every year, flu vaccine manufacturers have to guess what strains to target next season, with varying success. &lt;a href="https://www.cidara.com/" rel="noopener noreferrer" target="_blank"&gt;Cidara Therapeutics&lt;/a&gt; believes it may have a better alternative. President and CEO Jeff Stein explains how Cidara's laser-like focus on developing CD388, a single-dose antiviral targeting all flu strains, has brought the 40-person company on the verge of a public health breakthrough.&lt;/p&gt;&lt;p&gt;&lt;a href="https://www.cidara.com/news/cidara-therapeutics-announces-positive-topline-results-from-its-phase-2b-navigate-trial-evaluating-cd388-a-non-vaccine-preventative-of-seasonal-influenza/" rel="noopener noreferrer" target="_blank"&gt;Cidara announces positive topline results from its phase 2b NAVIGATE trial evaluating CD388&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;a href="https://www.cidara.com/about/#leadership" rel="noopener noreferrer" target="_blank"&gt;President and CEO Jeff Stein Bio&lt;/a&gt;&lt;/p&gt;</description>

Cidara’s pursuit of universal flu protection with a single dose

Perspectives from the cutting edge of biotech and pharma.

The fast-changing world of biopharma places a premium on trusted market insights from industry experts who can turn change into a competitive advantage. Stay ahead of the curve with our latest podcast series.

Lead today. Define tomorrow.

Pathfinders in Biopharma

Details

Recent Episodes